



**Pfizer Sponsored Abstracts**  
**2023 IDWeek Annual Meeting**  
 Last Updated: October 6, 2023

Title/Abstract Number	Presenter	Date/Time	Location
<b>IDWEEK PRESS PROGRAM</b>			
1942 - Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV Among US Infants	Amy W. Law, PharmD	Oct 13 2:15 - 2:30 PM US ET	104 ABC
<b>ORAL PRESENTATIONS</b>			
1019 - Respiratory Syncytial Virus (RSV) Diagnoses in Hospitalized Patients Increases when Additional Specimen Types are Added to Nasopharyngeal Swab: Results from the RSV in Adults Multispecimen Study	Elizabeth Begier, MD, MPH	Oct 12 3:15 - 3:33 PM US ET	104 ABC
1941 - Coadministration of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine with Influenza Vaccine in Older Adults	James Baber, MBChB, MPH	Oct 13 2:00 - 2:15 PM US ET	104 ABC
1944 - Tolerability and Safety of 20-Valent Pneumococcal Conjugate Vaccine (PCV20) in Infants and Older Children in Global Studies	Kathleen McElwee, MD, MPH	Oct 13 2:45 - 3:00 PM US ET	104 ABC
1948 - Rise of <i>Candida auris</i> Infections Worldwide and Trends on the Activity of Fosmanogepix and Comparator Agents Against <i>C. auris</i> Causing Invasive Infections	Cecilia G. Carvalhaes, MD, PhD	Oct 13 2:30 - 2:45 PM US ET	102 AB
1949 - Activity of Aztreonam-Avibactam Against <i>Enterobacterales</i> Resistant to Recently Approved Beta-Lactamase Inhibitor Combinations Collected Worldwide (ex-US: 2020-2022)	Helio S. Sader, MD, PhD, FIDSA	Oct 13 2:45 - 3:00 PM US ET	102 AB
2890 - Pharmacokinetics, Safety, and Efficacy of Ceftazidime-Avibactam in Neonates and Young Infants with Bacterial Infections: Results from a Phase 2a, 2-part, Open-label, Non-randomized, Multicenter Trial	Richard D. England, MD	Oct 14 2:05 – 2:15 PM US ET	254 AB
2893 - Efficacy and Safety of Aztreonam-Avibactam for the Treatment of Serious Infections Due to Gram-Negative Bacteria, Including Metallo- $\beta$ -Lactamase-Producing Pathogens: Phase 3 REVISIT Study	Yehuda Carmeli, PhD	Oct 14 2:35 - 2:45 PM US ET	254 AB



POSTERS			
RSV			
260 - Durability of Antibody Responses to RSV in Older Adults Following Hospitalization for Acute Respiratory Infection	Caroline Ciric, BS	Oct 12 12:15 - 1:30 PM US ET	Hall B + C
888 - Estimation of the Incidence of RSV-attributable Circulatory and Respiratory Hospital Admissions in Adults in Germany Between 2015–2019, Overall and for Specific Conditions	Caihua Liang, MD, PhD	Oct 12 12:15 - 1:30 PM US ET	Hall B + C
892 - Epidemiology, Clinical Features, and Outcomes of Rhinovirus/Enterovirus in Older Adults Hospitalized with Acute Respiratory Infections and Those with CHF and COPD Exacerbations	Gabby Ess	Oct 12 12:15 - 1:30 PM US ET	Hall B + C
1630 - Clinical Profile of Acute Respiratory Illness (ARI) Events in the Phase 3 Trial The RSV Vaccine Efficacy Study in Older Adults Immunized Against RSV Disease (RENOIR)	Elliot N. DeHaan, MD	Oct. 13 12:15 - 1:30 PM US ET	Hall B + C
1632 - Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults	Daniel P. Eiras. MD, MPH	Oct 13 12:15 - 1:30 PM US ET	Hall B + C
1634 - Respiratory Syncytial Virus-Associated Health Care Utilization in the Pivotal Phase 3 Trial RSV Vaccine Efficacy Study in Older Adults Immunized Against RSV Disease (RENOIR)	Kumar Ilangovan, MD, MSPH, MMCi	Oct 13 12:15 - 1:30 PM US ET	Hall B + C
2621 - Social Risk Factors for RSV-related Hospitalizations in Adults ≥50 Years of Age	Khalel De Castro	Oct 14 12:15 - 1:30 PM US ET	Hall B + C
2626 - Natural History of RSV Infection in Outpatient Episodes Among Adults in the United States Using an EHR Data Source by COVID-19 Era	Diana Garofalo, PhD, MPH	Oct 14 12:15 - 1:30 PM US ET	Hall B + C
2627 - Natural History of RSV Infection in Outpatient Episodes Among Children in the United States Using Two EHR Data Sources by COVID-19 Era	Diana Garofalo, PhD, MPH	Oct 14 12:15 - 1:30 PM US ET	Hall B + C
2629 - Estimation of Hospitalization and Mortality Burden of RSV in Adults in Spain Between 2015–2019	Caihua Liang, MD, PhD	Oct 14 12:15 - 1:30 PM US ET	Hall B + C
2634 - All-Cause Hospitalization Following Outpatient Episodes for RSV Among Adults in the United States Using an Integrated EHR-Claims Data Source	Diana Garofalo, PhD MPH	Oct 14 12:15 - 1:30 PM US ET	Hall B+C
2650 - Characteristics of In-Hospital Care and Immediate Post-Discharge Care Status Among Older Adults Hospitalized with Respiratory Syncytial Virus Infection, Seasonal Influenza, Acute Myocardial Infarction, and Stroke in the US	Reiko Sato, PhD	Oct 14 12:15 - 1:30 PM US ET	Hall B + C



<b>COVID-19</b>			
361 - Evaluation of Resistance to Nirmatrelvir/Ritonavir in Evaluation of Protease Inhibition for COVID-19 (EPIC) High-Risk and Standard-Risk Clinical Trials	Mary Lynn Baniecki, PhD	Oct 12 12:15 - 1:30 PM US ET	Hall B + C
362 - Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given As A Booster (Dose 4) to Toddlers and Children 6 Months to < 5 Years of Age Who Previously Received Original BNT162b2 as a 3-Dose Primary Series	Justice Kofi Boakya-Appiah, MD	Oct 12 12:15 - 1:30 PM US ET	Hall B + C
385 - Safety and Immunogenicity of a Variant-adapted Bivalent (Original/Omicron BA.4/BA.5) BNT162b2 COVID-19 Vaccine Given as a Booster (Dose 4) to 5- to 11-Year-Old Children Who Previously Received 3 Doses of Original BNT162b2	Emily Wasserman, MD	Oct 12 12:15 - 1:30 PM US ET	Hall B + C
419 - Viral SARS-CoV-2 Rebound Rates in Linked Commercial Pharmacy-based SARS-CoV-2 RT-qPCR Testing and Healthcare Claims	Shishi Luo, PhD	Oct 12 12:15 - 1:30 PM US ET	Hall B + C
430 - Clinical Features and Outcomes of COVID-19 Hospitalized Adults by Variant	Maria A. Perez	Oct 12 12:15 - 1:30 PM US ET	Hall B + C
447 - Clinical Features, Risk Factors, and Outcomes of COVID - 19 in Immunocompromised Adults Hospitalized with Acute Respiratory Infection	Elizabeth G. Taylor, BS Psychology	Oct 12 12:15 - 1:30 PM US ET	Hall B + C
516 - A Systematic Literature Review Evaluating Real-World Use of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Death	Ashley S. Cha-Silva, PharmD, MS	Oct 12 12:15 - 1:30 PM US ET	Hall B + C
522 - Real-World, Retrospective Descriptive Study of COVID-19 Outpatient Therapeutic Uptake in High-Risk Patients Subsequently Hospitalized for COVID-19 During the Omicron Period in the US	Florin Draica, MD	Oct 12 12:15 - 1:30 PM US ET	Hall B + C
532 - Nirmatrelvir/Ritonavir Versus Placebo in Unvaccinated and Vaccinated High Risk Patients	Heidi Leister-Tebbe, BSN	Oct 12 12:15 - 1:30 PM US ET	Hall B + C
2364 - Predictive Ability of mRNA COVID-19 Vaccines Against COVID-19 Disease Severity	Ashley Lew, BA	Oct 14 12:15 - 1:30 PM US ET	Hall B + C
<b>Pneumococcal Disease</b>			
1149 - Contribution of <i>S.pneumoniae</i> Serotypes in Adults with Invasive Pneumococcal Disease (IPD) and Pneumococcal Community-acquired Pneumonia (pCAP)	Kevin Apodaca, MPH	Oct. 13 12:15 - 1:30 PM US ET	Hall B + C



1728 - Immune Responses to Cross-Reactive Serotypes 6C and 15C After 20-Valent Pneumococcal Conjugate Vaccine in Infants	Mary J. Kline, MD	Oct. 13 12:15 - 1:30 PM US ET	Hall B + C
1737 - Cost-Effectiveness Analysis of Catch-up Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine	Ray Farkouh, PhD	Oct. 13 12:15 - 1:30 PM US ET	Hall B + C
1738 - Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US	Ray Farkouh, PhD	Oct. 13 12:15 - 1:30 PM US ET	Hall B + C
1740 - Healthcare Providers' Preferences for Pediatric Pneumococcal Vaccination Recommendations in the United States	Jeffrey T. Vietri, PhD	Oct. 13 12:15 - 1:30 PM US ET	Hall B + C
2604 - Contact with School-Aged Children is a Major Risk Factor for Pneumococcal Colonization in Older Adults	Anne L. Wyllie, PhD	Oct. 14 12:15 - 1:30 PM US ET	Hall B + C
2658 - Mortality Among Children Hospitalized with Suspected Pneumonia during the COVID-19 Pandemic in India (PREVAIL study)	Yangyupei Yang, MHS	Oct. 14 12:15 - 1:30 PM US ET	Hall B + C
<b>Lyme Disease</b>			
1631 - Background Incidence Rates of Health Outcomes Relevant to Vaccine Monitoring in Lyme Disease Endemic and Non-endemic US Regions Using Administrative Claims Data	Jill Dreyfus, PhD, MPH	Oct 13 12:15 - 1:30 PM US ET	Hall B + C
<b>Anti-Infectives</b>			
2119 - <i>In Vitro</i> Activity of Aztreonam-Avibactam Against <i>Enterobacteriales</i> Isolated from Pediatric and Adult Patients Collected During the ATLAS Global Surveillance Program, 2017-2021	Mark Estabrook, PhD	Oct 14 12:15 - 1:30 PM US ET	Hall B + C
2127 - <i>In Vitro</i> Activities of Ceftaroline and Comparator Agents Against Bacterial Pathogens Frequently Causing Community-Acquired Respiratory Tract Infections in Patients from a Global Population: ATLAS Surveillance Program 2018-2021	Meredith Hackel, PhD	Oct 14 12:15 - 1:30 PM US ET	Hall B + C
2128 - <i>In Vitro</i> Activity of Ceftibuten-Avibactam and Comparator Agents Against Resistant <i>Enterobacteriales</i> from UTIs Collected Globally as Part of the ATLAS Surveillance Program, 2022	Meredith Hackel, PhD	Oct 14 12:15 - 1:30 PM US ET	Hall B + C
2146 - Antimicrobial Activity of Aztreonam-avibactam, Ceftazidime-avibactam, and Meropenem-vaborbactam Against <i>Enterobacteriales</i> Causing Bloodstream Infection in US Medical Centers (2020–2022)	Helio S. Sader, MD, PhD, FIDSA	Oct 14 12:15 - 1:30 PM US ET	Hall B + C



2149 - <i>In Vitro</i> Activity of Aztreonam-avibactam and Comparator Agents Against Carbapenem-Resistant <i>Enterobacterales</i> with and Without Carbapenemases, ATLAS Global Surveillance Program, 2017–2021	Mark G. Wise, PhD	Oct 14 12:15 - 1:30 PM US ET	Hall B + C
2151 - <i>In Vitro</i> Activity of Ceftazidime-Avibactam and Comparator Agents Against <i>Pseudomonas aeruginosa</i> Collected from Patients with Presumed Hospital- and Community-Acquired Respiratory Tract Infections: ATLAS Global Surveillance Program, 2017-2021	Mark G. Wise, PhD	Oct 14 12:15 - 1:30 PM US ET	Hall B + C
2826 - Epidemiology of Extended Spectrum Beta-lactamase (ESBL)-producing <i>Enterobacterales</i> and Antimicrobial Resistance in Urinary Tract Infection (UTI) and Acute Pyelonephritis (AP)	Maria M. Fernandez, PhD, MBA	Oct 14 12:15 - 1:30 PM US ET	Hall B + C